[Federal Register Volume 77, Number 147 (Tuesday, July 31, 2012)]
[Notices]
[Pages 45363-45366]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-18651]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office
[[Page 45364]]
of Technology Transfer, National Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301-
496-7057; fax: 301-402-0220. A signed Confidential Disclosure Agreement
will be required to receive copies of the patent applications.
Glial Cell Line-Derived Neurotrophic Factor Opposite Strand (GDNFOS)
for Treatment of Neurodegenerative Diseases
Description of Technology: Glial cell line-derived neurotrophic
factor (GDNF) is a small human protein encoded by the GDNF gene. GDNF
has been effective therapy in laboratory animal models of Parkinson's
disease and protects several types of neurons in the brain and
peripheral nervous system. The NIDA inventors have discovered primate-
specific GDNFOS, encoded by the opposite strand of glial cell derived
neurotrophic factor (GDNF) gene. The GDNFOS gene encodes for novel
peptides that was found to be reduced in human middle temporal gyrus of
Alzheimer's disease brains. These secreted growth proteins have
potential neurotrophic activity and they might play a synergistic role
in neuroprotective effects of GDNF in human brain. The NIDA inventors
have also developed antibody against GDNFOS3 and generated compounds
that have potential pharmaceutical use. The compounds consist of GDNFOS
nucleic acid transcripts, GDNFOS protein or a functional fragment for
treatment of human neurodegenerative diseases.
Potential Commercial Applications
Synergistic role in neuroprotective effects of GDNF.
Alzheimer's disease, Parkinson's disease, Amyotrophic
lateral sclerosis, multiple sclerosis and diseases of peripheral organs
such as diabetes mellitus type 1.
Competitive Advantages
Secreted novel growth peptides.
An antibody against GDNFOS3 was developed.
Development Stage
Early-stage.
Pre-clinical.
In vitro data available.
Inventors: Qing-Rong Liu, Mikko Airavaara, Barry Hoffer, Brandon K
Harvey (all of NIDA).
Publication: Airavaara M, et al. Identification of novel GDNF
isoforms and cis-antisense GDNFOS gene and their regulation in human
middle temporal gyrus of Alzheimer disease. J Biol Chem. 2011 Dec
30;286(52):45093-102. [PMID 22081608]
Intellectual Property: HHS Reference No. E-044-2012/0--U.S.
Provisional Application No. 61/619, 296 filed 02 Apr 2012.
Licensing Contact: Betty B. Tong, Ph.D.; 301-594-6565;
[email protected].
Collaborative Research Opportunity: The National Institute on Drug
Abuse is seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate or
commercialize GDNFOS peptide and non-coding RNAs as therapeutic agents
for neurodegenerative diseases. For collaboration opportunities, please
contact Vio Conley at [email protected].
Increased Therapeutic Effectiveness of Immunotoxins That Use Toxin
Domains Lacking Human B-cell Epitopes
Description of Technology: Immunotoxins kill cancer cells while
allowing healthy, essential cells to survive. As a result, patients
receiving an immunotoxin are less likely to experience the deleterious
side-effects associated with non-discriminate therapies such as
chemotherapy or radiation therapy. Unfortunately, the continued
administration of immunotoxins often leads to a reduced patient
response due to the formation of neutralizing antibodies against
immunogenic epitopes contained within Pseudomonas exotoxin A (PE). To
improve the therapeutic effectiveness of PE-based immunotoxins through
multiple rounds of drug administration, NIH inventors have sought to
identify and remove the human B-cell epitopes within PE. Previous work
demonstrated that the removal of the murine B-cell and T-cell epitopes
from PE reduced the immunogenicity of PE and resulted in immunotoxins
with improved therapeutic activity. This technology involves the
identification and removal of major human B-cell epitopes on PE by
mutation or deletion. Considering these immunotoxins will be
administered to humans, the removal of human immunogenic epitopes is
important. The resulting PE-based immunotoxins have increased
resistance to the formation of neutralizing antibodies, and are
expected to have improved therapeutic efficacy.
Potential Commercial Applications
Essential component of immunotoxins.
Treatment of any disease associated with increased or
preferential expression a specific cell surface receptor.
Specific diseases include hematological cancers, lung
cancer, ovarian cancer, breast cancer, and head and neck cancers.
Competitive Advantages
PE variants now include the removal of human B-cell
epitopes, further reducing the formation of neutralizing antibodies
against immunotoxins which contain the PE variants.
Less immunogenic immunotoxins result in improved
therapeutic efficacy by permitting multiple rounds of administration in
humans.
Targeted therapy decreases non-specific killing of
healthy, essential cells, resulting in fewer non-specific side-effects
and healthier patients.
Development Stage: Pre-clinical.
Inventors: Ira H. Pastan et al. (NCI).
Publication: Liu W, et al. Recombinant immunotoxin engineered for
low immunogenicity and antigenicity by identifying and silencing human
B-cell epitopes. Proc Natl Acad Sci USA. 2012 Jul 17;109(29):11782-7.
[PMID 22753489]
Intellectual Property: HHS Reference No. E-263-2011/0--U.S.
Provisional Application No. 61/535,668 filed 16 Sep 2011.
Related Technologies
PCT Patent Publication WO 2011/032022 (HHS Reference No.
E-269-2009/0-PCT-02).
US Patent Publication US 20100215656 A1 (HHS Reference No.
E-292-2007/0-US-06).
US Patent Publication US 20090142341 A1 (HHS Reference No.
E-262-2005/0-US-06).
Multiple additional patent families.
Licensing Contact: David A. Lambertson, Ph.D.; 301-435-4632;
[email protected].
Collaborative Research Opportunity: The National Cancer Institute
is seeking statements of capability or interest from parties interested
in collaborative research to further develop, evaluate or commercialize
this technology. For collaboration opportunities, please contact John
Hewes, Ph.D. at [email protected].
Novel Nitroxyl (HNO) Releasing Compounds and Their Use in Treating
Diseases
Description of Technology: Nitroxyl (HNO) is a chemical species
that exhibits distinct biological properties in comparison to its
oxidized product, nitric oxide (NO). Previous investigations have
revealed that the
[[Page 45365]]
distinct properties of HNO make it a tempting species for wide
therapeutic application as it has shown potential in the treatment of
heart failure, cancer, and other diseases in various animal and in
vitro models. Non-steroidal anti-inflammatory drugs (NSAIDs), such as
aspirin and ibuprofen, are compounds that inhibit cycloxygenase (COX)-
mediated conversion of arachidonic acids to prostagladins. NSAIDs are
known for their analgesic properties and are therapeutically involved
in many physiological functions, including the inhibition of chronic
pain and inflammation inhibition, prevention of heart disease, renal
function, and cancer. Prolonged use of NSAIDs can lead to serious
gastrointestinal and renal side effects, including ulcer perforation,
upper gastrointestinal bleeding, and death, which has limited NSAID
therapies.
The instant invention described HNO-releasing NSAIDs, which combine
the potential therapeutic benefits of HNO and NSAIDs without the
toxicities associated with chronic NSAID use. These HNO-releasing
NSAIDs provide a reliable controlled release of HNO making them
desirable HNO prodrugs. The instant invention disclosed various HNO-
releasing NSAIDs and methods of treating or preventing various
disorders with these compositions, such as cardiovascular disorders,
cancers, pain, inflammation, and alcoholism.
Potential Commercial Applications
Treatment of cancer.
Treatment of cardiovascular disease.
Aversion therapy for alcoholism.
Competitive Advantages
Combination of therapeutic benefits of HNO and NSAIDs.
Alleviated toxicity associated with chronic NSAID use.
Controlled release of HNO.
Development Stage
Early-stage.
Pre-clinical.
Inventors: David A. Wink and Larry K. Keefer (NCI).
Publication
Miranda KM, et al. Comparison of the NO and HNO donating
properties of diazeniumdiolates: primary amine adducts release HNO
in vivo. J Med Chem. 2005 Dec 29;48(26):8220-8. [PMID 16366603]
Intellectual Property: HHS Reference No. E-019-2010/2--
International Patent Application PCT/US2011/029072 filed 18 Mar 2011.
Licensing Contact: Betty B. Tong, Ph.D.; 301-594-6565;
[email protected].
Polyclonal Antibodies for the Specialized Signaling G Protein, Gbeta5
Description of Technology: Researchers at NIDDK have developed
polyclonal antibodies against the G protein, Gbeta5. Gbeta5 is a unique
and highly specialized G protein that exhibits much less homology than
other Gbeta isoforms (~50%) and is preferentially expressed in brain
and neuroendocrine tissue. It is expressed prominently in the neuronal
cell membrane, as well as in the cytosol and nucleus. Although this
distribution pattern suggests that Gbeta5 may shuttle information
between classical G protein-signaling elements at the plasma membrane
and the cell interior, its function in the brain is largely unknown.
The antibodies were separately generated in rabbits to KLH-
conjugates of peptides from the N-terminus of Gbeta5 (antibody ATDG)
and the C-terminus of Gbeta5 (antibody SGS). The antibodies can be used
for immunoblotting (ATDG, SGS), and immunoprecipitation (ATDG). They
can be used to facilitate our understanding of the unique biology and
function of Gbeta5 in brain and neurons.
Potential Commercial Applications: These antibodies can be used for
research purposes (immunoblotting, immunoprecipitation) by those
studying the biology and function of Gbeta5.
Competitive Advantages: Very specific antibodies to study Gbeta5
and G protein signaling.
Development Stage: In vitro data available.
Inventors: William Simonds and Jianhua Zhang (NIDDK).
Publications
1. Zhang JH and Simonds WF. Copurification of brain G-protein
beta5 with RGS6 and RGS7. J Neurosci. 2000 Feb 1;20(3):RC59. [PMID
10648734]
2. Zhang JH, et al. Nuclear localization of G protein beta 5 and
regulator of G protein signaling 7 in neurons and brain. J Biol
Chem. 2001 Mar 30;276(13):10284-9. [PMID 11152459]
3. Zhang S, et al. Selective activation of effector pathways by
brain-specific G protein beta5. J Biol Chem. 1996 Dec
27;271(52):33575-9. [PMID 8969224]
4. Zachariou V, et al. An essential role for DeltaFosB in the
nucleus accumbens in morphine action. Nat Neurosci. 2006
Feb;9(2):205-11. [PMID 16415864]
Intellectual Property: HHS Reference No. E-192-2006/0--Research
Tool. Patent protection is not being pursued for this technology.
Licensing Contact: Jaime Greene, M.S.; 301-435-5559;
[email protected].
Polyclonal Antibodies for the Gbeta5-Associated Regulator of G Protein
Signaling Protein, RGS7
Description of Technology: Researchers at NIDDK have developed
polyclonal antibodies against the Regulator of G Protein Signalling
(RGS) protein, RGS7. RGS7 binds tightly to Gbeta5, a unique and highly
specialized G protein that exhibits much less homology than other Gbeta
isoforms (~50%). RGS7 is preferentially expressed in brain and
neuroendocrine tissue. Like Gbeta5, RGS7 is expressed prominently in
the cell membrane, as well as in the cytosol. Although this
distribution pattern suggests that complexes containing Gbeta5 and RGS7
may shuttle information between classical G protein-signaling elements
at the plasma membrane and the cell interior, the function of the
complex in the brain is largely unknown.
The antibodies were generated in rabbits to a glutathione S-
transferase (GST) fusion protein with residues 312-469 of bovine RGS7
(antibody 7RC-1) and react with human and rodent RGS7. The antibodies
(7RC-1) can be used for immunoblotting and immunoprecipitation. They
can be used to facilitate our understanding of the function of Gbeta5/
RGS7 complexes in brain and neurons.
Potential Commercial Applications: These antibodies can be used for
research purposes (immunoblotting, immunoprecipitation) by those
studying the biology and function of RGS7.
Competitive Advantages: High-titer, multi-epitope antibodies to
study RGS7 and RGS7/Gbeta5 complexes and G protein signaling.
Development Stage: In vitro data available.
Inventors: William Simonds and Jianhua Zhang (NIDDK).
Publications
1. Rojkova AM, et al. Ggamma subunit selective G protein beta 5
mutant defines regulators of G protein signaling binding requirement
for nuclear localization. J Biol Chem. 2003 Apr 4;278(14):12507-12.
[PMID 12551930]
2. Cao Y, et al. Retina Specific GTPase Accelerator RGS11/
Gbeta5S/R9AP is a Constitutive Heterotrimer Selectively Targeted to
mGluR6 in ON-Bipolar Neurons. J Neurosci 2009 July 22; 29 (29):
9301-13. [PMID 19625520]
3. Anderson GR, et al. Changes in striatal signaling induce
remodeling of RGS complexes containing Gbeta5 and R7BP subunits. Mol
Cell Biol. 2009 Jun;29(11): 3033-44. [PMID 19332565]
4. Panicker LM, et al. Nuclear localization of the G protein
beta5/R7-regulator of G protein signaling protein complex is
dependent on R7 binding protein. J
[[Page 45366]]
Neurochem. 2010 Jun;113(5):1101-12. [PMID 20100282]
Intellectual Property: HHS Reference No. E-077-2011/0--Research
Tool. Patent protection is not being pursued for this technology.
Licensing Contact: Jaime Greene, M.S.; 301-435-5559;
[email protected].
Dated: July 24, 2012.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2012-18651 Filed 7-30-12; 8:45 am]
BILLING CODE 4140-01-P